Dipexium Pharmaceuticals' Locilex® Microbiology Data Presented at ASM Microbe 2016 Conference
NEW YORK, June 20, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), and research collaborator, R. M. Alden Research Laboratory, announced that data from two new Locilex® microbiology studies were presented at the American Society for Microbiology's Microbe conference in Boston, Massachusetts, June 16-20, 2016.
In the first poster presentation entitled "In Vitro Activity of Pexiganan and Eight Comparator Antimicrobials against 234 Isolates Including 93 Pasteurella species and 50 Anaerobic Bacteria Recovered from Animal Bite Wounds," researchers concluded that pexiganan, the active pharmaceutical ingredient in Locilex, demonstrated a high level of activity against a diverse group of aerobic and anaerobic organisms commonly found in animal bite wounds. Pexiganan's MIC90 values for each of the organism groups studied, including Pasteurella, which is known to be present in over 50% of all dog and cat bite infections, were below the concentration of pexiganan in Locilex's topical cream formulation, indicating that Locilex should have the ability to inhibit these infecting organisms in animal bite infections amenable to treatment with a topical antimicrobial. In the U.S., it is estimated that there are approximately 4.9 million animal bites per year, leading to 300,000 emergency department visits and 10,000 hospitalizations that often require antimicrobial therapy.
In the second poster presentation entitled "In Vitro Activity of Pexiganan and Ten Comparator Antimicrobials against 503 Anaerobic Bacteria Recovered from Skin and Skin Structure Infections (SSSI)," investigators concluded that pexiganan demonstrated potent in vitro activity against a broad spectrum of contemporary Gram-positive and Gram-negative anaerobic bacteria found in difficult-to-treat skin and skin structure infection samples from North America and Europe. Pexiganan's MIC90 values for each of the organism groups studied were again below the concentration of pexiganan in Locilex's topical cream formulation, indicating that pexiganan in the current formulation should have the ability to inhibit most infecting organisms in superficial skin and wound infections amenable to treatment with a topical antimicrobial.
Robert J. DeLuccia, Executive Chairman of Dipexium, said, "Pexiganan has repeatedly shown anti-microbial activity across a broad spectrum of pathogenic organisms, including those that are frequent pathogens in skin and skin structure infections. These new data corroborate previous data and confirm that pexiganan's spectrum of activity covers not just common aerobic bacteria but also a wide variety of anaerobic organisms that may cause more serious wound infections." He added, "Since currently available topical antibiotics are not typically used to treat skin infections caused by anaerobic organisms, this could provide an important clinical advantage."
Copies of both poster presentations can be found on Dipexium Pharmaceuticals' website at www.dipexiumpharmaceuticals.com/locilex/key-publications.
About Dipexium Pharmaceuticals, Inc.
Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) is a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide. Initially, Locilex® is targeted for the treatment of mild infections of diabetic foot ulcers. Based on a compilation of available clinical and microbiology data, Locilex® is also considered a promising product candidate to treat other mild and moderate skin and skin structure infections, including infected decubitus ulcers, infected burns, infected surgical wounds, infected animal bites and nasal colonization of methicillin-resistant staphylococcus aureus (MRSA).
Cautionary Note on Forward-Looking Statements
This press release and any statements of representatives and partners of Dipexium Pharmaceuticals, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission and those that relate to the Company's ability to leverage the expertise of employees and partners to assist the Company in the execution of its strategy. Actual results (including, without limitation, the timing for and results of the clinical trials and proposed NDA submission for Locilex®) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Company Contacts:
David P. Luci
President & Chief Executive Officer
Dipexium Pharmaceuticals, Inc.
212-269-2834
[email protected]
David Garrett
Vice President, Finance & Corporate Development
Dipexium Pharmaceuticals, Inc.
212-269-2834
[email protected]
© 2016 Dipexium Pharmaceuticals, Inc. All rights reserved.
SOURCE Dipexium Pharmaceuticals, Inc.
Share this article